Zymeworks
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 277
- Market Cap
- $822M
- Introduction
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
Zymeworks Inc. advances its solid tumor strategy, nominating ZW209 as its fifth development candidate, 18 months ahead of schedule. The company expands into autoimmune, inflammatory diseases, and hematology oncology, leveraging its Azymetric™ technology. ZW1528, targeting respiratory inflammation, and other candidates like ZW171, ZW191, ZW220, and ZW251, show promise in treating various cancers. Zymeworks plans to submit INDs for these candidates, aiming for clinical trials starting 2025-2026.
Zymeworks Hosts R&D Day Highlighting Continued Progress in Drug Development
Zymeworks Inc. announces progress in its R&D, including the nomination of ZW209 as its fifth development candidate in solid tumors, 18 months ahead of schedule. The company expands into autoimmune and inflammatory diseases (AIID) and hematology oncology, leveraging its Azymetric™ technology. ZW1528, targeting respiratory inflammation, is highlighted. Zymeworks plans to advance five drug candidates into clinical trials for solid tumors by 2026, with IND applications for ZW209, ZW220, and ZW251 expected by 2025-2026.
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress In Oncology Programs And Expansion Into Autoimmune And Inflammatory Diseases
Zymeworks Inc. accelerates its '5 by 5' solid tumor strategy, nominating ZW209 as its fifth development candidate, 18 months ahead of schedule. The company expands into autoimmune and inflammatory diseases (AIID) and hematology oncology, leveraging its AzymetricTM platform. ZW1528, targeting respiratory inflammation, marks its first AIID candidate. Zymeworks plans to submit INDs for ZW209, ZW220, and ZW251 by 2026, advancing its pipeline in solid tumors, AIID, and hematology oncology.
Jazz Pharmaceuticals to Showcase Breakthrough Cancer Drug Ziihera Following FDA Approval
Jazz Pharmaceuticals to host a webcast on Dec 11, 2024, to discuss Ziihera® (zanidatamab-hrii), a chemotherapy-free dual HER2-targeted bispecific antibody for biliary tract cancer (BTC), approved by the FDA on Nov 20, 2024.
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on ...
Jazz Pharmaceuticals to host a webcast on December 11, 2024, to discuss clinical data, patient need, and commercialization strategy for Ziihera® (zanidatamab-hrii), a chemotherapy-free dual HER2-targeted bispecific antibody for biliary tract cancer (BTC), recently approved by the FDA.
Personalized Medicines Market to Surpass Valuation of USD
SkyQuest projects the global personalized medicines market to reach USD 1352.81 Billion by 2031, with a CAGR of 11.40% driven by innovative therapies, partnerships, and advancements in genomics and AI-powered diagnostics. North America leads due to favorable regulatory frameworks and high R&D spending.
Zymeworks Gains Buy Rating Amid FDA Approval and Market Expansion Potential for Zanidatamab
David Martin PhD maintains Buy rating on Zymeworks (ZYME) with $19.50 target, citing FDA approval for zanidatamab and ongoing Phase 3 trial. Leerink Partners also maintains Buy rating with $26.00 target.
FDA clears drug for rare and deadly GI cancer developed by Canadian firm Zymeworks
FDA approves Zihera, a non-chemotherapy treatment for metastatic HER2-positive biliary tract cancer, developed by Zymeworks. Jazz Pharmaceuticals secured commercialization rights for $375 million USD upfront, with additional royalties. Zihera showed significant tumor shrinkage in a Phase 2b trial, with benefits lasting an average of 15 months.
Jazz secures FDA nod for Ziihera to treat HER2-positive BTC
Zymeworks and Jazz Pharmaceuticals receive FDA accelerated approval for Ziihera (zanidatamab-hrii) in treating HER2-positive biliary tract cancer (BTC). Ziihera, a dual HER2-targeted bispecific antibody, is the first chemotherapy-free treatment for BTC. Zymeworks earns $25m milestone payment and is eligible for up to $1.3625b in milestones and royalties. FDA approval supported by HERIZON-BTC-01 trial data, showing 52% objective response rate and 14.9 months median duration of response.
FDA approves cancer drug developed by B.C.'s Zymeworks
The FDA granted accelerated approval to Zymeworks Inc.'s Ziihera for treating biliary tract cancer, triggering a $25M milestone payment from Jazz Pharmaceuticals. Zymeworks could earn over $1B in milestone payments and royalties. Ziihera is a variation of Zanidatamab, developed for various cancers, and marks Zymeworks' first FDA-approved therapy.
© Copyright 2025. All Rights Reserved by MedPath